Schiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Mice

Basit Öğe Kaydı
dc.authoridKilic, Ertugrul/0000-0001-6494-8923
dc.authoridOrhan, Cemal/0000-0003-4138-7689
dc.authoridDoğan, Ayşegül/0000-0003-4160-2270
dc.authoridSahin, Kazim/0000-0001-9542-5244
dc.authoridTelci, Dilek/0000-0002-2793-6533
dc.authoridbasak, nese/0000-0001-5566-8321
dc.authoridSahin, Fikrettin/0000-0003-1503-5567
dc.authorwosidKilic, Ertugrul/W-4563-2018
dc.authorwosidOrhan, Cemal/Q-2086-2015
dc.authorwosidDoğan, Ayşegül/AAD-3223-2019
dc.authorwosidSahin, Kazim/D-5625-2009
dc.authorwosidTelci, Dilek/N-5053-2019
dc.authorwosidDemirci, Selami/AAC-9963-2020
dc.authorwosidbasak, nese/ABH-5495-2020
dc.contributor.authorDogan, Aysegul
dc.contributor.authorDemirci, Selami
dc.contributor.authorTurkmen, Nese Basak
dc.contributor.authorCaglayan, Ahmet Burak
dc.contributor.authorAydin, Safa
dc.contributor.authorTelci, Dilek
dc.contributor.authorKilic, Ertugrul
dc.date.accessioned2024-08-04T20:42:31Z
dc.date.available2024-08-04T20:42:31Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBACKGROUNDProstate cancer which is the second most common cause of death among men has a high incidence in recent years. Current therapeutic regimens should be improved to overcome drug resistance. At the metastatic stage, tumors become refractory to established chemotherapeutic treatments and cause serious problems at the clinics. Development of new drug molecules that are able to transport through the membrane easily and kill tumor cells rapidly is of great interest. METHODIn the current study, a novel Heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used for prostate cancer treatment in vivo. Tramp-C1 cells injected animals were subjected to chemotherapeutic formulation treatment and results were analyzed by toxicology analysis, tumor volume measurements, and histopathological analysis. 0.5mg/kg Schiff base was selected and combined with 0.05% P85 according to the toxicology analysis showing the enzyme levels, blood parameters, and multiple organ toxicity. RESULTSResults demonstrated that Heterodinuclear copper(II)Mn(II) complex-P85 combination decreased tumor formation and tumor volume steadily over the course of experiments. CONCLUSIONSOverall, Heterodinuclear copper(II)Mn(II) complex-P85 exerted remarkable anti-cancer activity in vivo in C57/B16 mice. Prostate 76:1454-1463, 2016. (c) 2016 Wiley Periodicals, Inc.en_US
dc.identifier.doi10.1002/pros.23229
dc.identifier.endpage1463en_US
dc.identifier.issn0270-4137
dc.identifier.issn1097-0045
dc.identifier.issue15en_US
dc.identifier.pmid27338565en_US
dc.identifier.scopus2-s2.0-84977534680en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1454en_US
dc.identifier.urihttps://doi.org/10.1002/pros.23229
dc.identifier.urihttps://hdl.handle.net/11616/97399
dc.identifier.volume76en_US
dc.identifier.wosWOS:000384547100011en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofProstateen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSchiff baseen_US
dc.subjectpluronicen_US
dc.subjectP85en_US
dc.subjectprostate canceren_US
dc.subjecttramp-C1en_US
dc.titleSchiff Base-Poloxamer P85 Combination Prevents Prostate Cancer Progression in C57/Bl6 Miceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu